Skip to main content
SpringerLink
Log in

Persistent herpes simplex virus infection and mechanisms of virus drug resistance

  • Review
  • Published:
European Journal of Clinical Microbiology and Infectious Diseases Aims and scope Submit manuscript

Abstract

Herpes simplex virus (HSV) is susceptible to a variety of antiviral compounds, most of which are nucleoside analogues that interfere with DNA metabolism involving the virus enzymes DNA-polymerase and thymidine kinase. Single mutations in the virus genome give rise to resistant mutants following selection in vitro in the presence of a particular drug, and in this respect HSV is similar to several other viruses. Such mutants have been invaluable research tools. HSV is responsible for a variety of lesions which tend to be recurrent, owing to the special ability of the virus to remain latent in and reactivate from neural tissue. The consequences of this upon clinical resistance are discussed in the present review. In fact, clinical resistance in HSV infections has not yet become widespread but does appear to be especially important in immunocompromised patients, including those suffering from AIDS. HSV is proposed as an important model for the investigation of drug resistance in other, more complex organisms, and with respect to antiviral strategies against the human immunodeficiency virus.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Wildy, P., Field, H. J., Nash, A. A.: Classical herpes latency revisited. In: Mahy, B. W. J., Minson, A. C., Darby, G. K. (ed.): Virus persistence. Society for General Microbiology. Symposium 33, Cambridge University Press, Cambridge, 1982, p. 133–167.

    Google Scholar 

  2. Spivack, J. G., Fraser, N. W.: Expression of herpes simplex virus type 1 latency-associated transcripts in the trigeminal ganglia of mice during acute infection and reactivation of latent infection. Journal of Virolology 1988, 62: 1479–1485.

    Google Scholar 

  3. Roizman, B., Batterson, W.: Herpesviruses and their replication. In: Field, B. N., Knipe, D. M., Chanock, R. M., Melnick, J. L., Roizman, B., Shope, R. E. (ed.): Field's virology. Raven Press, New York, 1985, p. 497–526.

    Google Scholar 

  4. Whitley, R. J.: Treatment of human herpes virus infections with special reference to encephalitis. Journal of Antimicrobial Chemotherapy 1984, 14, Supplement A: 57–74.

    Google Scholar 

  5. Whitley, R. J., Levin, M., Barton, N., Hershey, B. J., Davis, G., Keeney, R. E., Whelchel, J., Diethelm, A. G., Kartus, P., Soong, S.-J.: Infections due to herpes simplex virus in the immunocompromised host: natural history and acyclovir therapy. Journal of Infectious Diseases 1984, 150: 323–329.

    Google Scholar 

  6. Mitsuya, H., Broder, S.: Strategies for antiviral therapy in AIDS. Nature 1987, 325: 773–778.

    Google Scholar 

  7. Hovi, T.: Successful selective inhibitors of viruses. In: Field, H. J. (Ed.): Antiviral agents: development and assessment of antiviral chemotherapy. CRC Press, Boca Raton, 1988, p. 1–21.

    Google Scholar 

  8. Oberg, B.: Antiviral effects of phosphonoformate (PFA, foscarnet sodium). Pharmacology and Therapeutics 1983, 19: 387–415.

    Google Scholar 

  9. Oberg, B.: Inhibitors of virus-specific enzymes. In: Stuart-Harris, C. H., Oxford, J. (ed.): Problems of antiviral therapy. Academic Press, London, 1983, p. 35–69.

    Google Scholar 

  10. Elion, G. B.: The biochemistry and mechanism of action of acyclovir. Journal of Antimicrobial Chemotherapy 1983, 12, Supplement B: 9–17.

    Google Scholar 

  11. Prusoff, W. H., Fischer, P. H.: Basis for the selective antiviral and antitumour activity of pyrimidine nucleoside analogues. In: Walker, R. T., De Clercq, E., Eckstein, F. (ed.): Nucleoside analogues, chemistry, biology, and medical applications. Plenum Press, New York, 1979, p. 281–318.

    Google Scholar 

  12. Kit, S.: Thymidine kinase. Microbiological Science 1985, 2: 369–375.

    Google Scholar 

  13. Oxford, J. S., Field, H. J., Reeves, D. S. (ed.): Drug resistance in viruses, other microbes and eukaryotes. Academic Press, London, 1986, p. iiiet seq.

    Google Scholar 

  14. Coen, D. M.: General aspects of virus drug resistance with special reference to herpes simplex virus. Journal of Antimicrobial Chemotherapy 1986, 18, Supplement B: 1–10.

    Google Scholar 

  15. Thomas, H. C., Scully, L. J.: Antiviral therapy in hepatitis B infection. British Medical Bulletin 1985, 41: 374–380.

    Google Scholar 

  16. Dubbs, D. R., Kit, S.: Mutant strains of herpes simplex deficient in thymidine kinase-inducing activity. Virology 1964, 22: 493–502.

    Google Scholar 

  17. Summers, W. P., Wagner, M., Summers, W. C.: Possible peptide chain termination mutants in thymidine kinase gene of a mammalian virus, herpes simplex virus. Proceedings of the National Academy of Sciences of the USA 1975, 72: 4081–4084.

    Google Scholar 

  18. Coleman, V. R., Tsu, E., Jawetz, E.: “Treatment resistance” to idoxuridine in herpetic keratitis. Proceedings of the Society for Experimental Biology and Medicine 1968, 129: 761–765.

    Google Scholar 

  19. Elion, G. B., Furman, J. A., Fyfe, J. A., De Miranda, P., Beauchamp, L., Schaeffer, H. J.: Selectivity of action of an antiherpetic agent, 9-(2-(hydroxyethoxymethyl)guanine. Proceedings of the National Academy of Sciences of the USA 1978, 74: 5716–5720.

    Google Scholar 

  20. Coen, D. M., Schaffer, P. A.: Two distinct loci confer resistance to acycloguanosine in herpes simplex virus type 1. Proceedings of the National Academy of Sciences of the USA 1980, 77: 2265–2269.

    Google Scholar 

  21. Schnipper, L. E., Crumpacker, C. S.: Resistance of herpes simplex virus to acycloguanosine: role of viral thymidine kinase and DNA polymerase loci. Proceedings of the National Academy of Sciences of the USA 1980, 77: 2270–2273.

    Google Scholar 

  22. Field, H., MacMillan, A., Darby, G.: The sensitivity of acyclovir-resistant mutants of herpes simplex virus to other antiviral drugs. Journal of Infectious Diseases 1981, 143: 281–285.

    Google Scholar 

  23. Field, H. J., Darby, G., Wildy, P.: Isolation and characterization of acyclovir-resistant mutants of herpes simplex virus. Journal of General Virology 1980, 49: 115–124.

    Google Scholar 

  24. Darby, G., Field, H. J., Salisbury, S. A.: Altered substrate specificity of herpes simplex virus thymidine kinase confers acyclovir-resistance. Nature 1981, 289: 81–83.

    Google Scholar 

  25. Larder, B. A., Cheng, Y.-C., Darby, G.: Characterization of abnormal thymidine kinases induced by drug-resistant strains of herpes simplex virus type 1. Journal of General Virology 1983, 64: 523–532.

    Google Scholar 

  26. Veerisetty, V., Gentry, G. A.: Alterations in substrate specificity and physicochemical properties of deoxythymidine kinase of a drug-resistant herpes simplex virus type 1 mutant. Journal of Virology 1983, 46: 901–908.

    Google Scholar 

  27. Larder, B. A., Derse, D., Cheng, Y.-C., Darby, G.: Properties of purified enzymes induced by pathogenic drug-resistant mutants of herpes simplex virus. Evidence for virus variants expressing normal DNA polymerase and altered thymidine kinase. Journal of Biological Chemistry 1983, 285: 2027–2033.

    Google Scholar 

  28. Darby, G., Larder, B. A., Inglis, M. M.: Evidence that the “active centre” of the herpes simplex virus thymiine kinase involves an interaction between three distinct regions of the polypeptide. Journal of General Virology 1986, 67: 753–758.

    Google Scholar 

  29. Kit, S., Sheppard, M., Ichimura, H., Nusinoff-Lehrman, S., Ellis, N. M., Fyfe, J. A., Otsuka, H.: Nucleotide sequence changes in the thymidine kinase gene of herpes simplex virus type 2 clones from a patient treated with acyclovir. Antimicrobial Agents and Chemotherapy 1987, 31: 1483–1490.

    Google Scholar 

  30. Inglis, M. M., Darby, G.: Analysis of the role of the cystein 171 residue in the activity of herpes simplex virus type 1 thymidine kinase by oligonucleotide-directed mutagenesis. Journal of General Virology 1987, 68: 39–46.

    Google Scholar 

  31. Coen, D. M., Chiou, H. C., Fleming, H. E., Jr., Leslie, L. K., Retondon, M. J.: Drug resistant and hypersensitive herpes simplex virus mutants: isolation and application to dissection of the pol locus. In: Rapp, F. (ed.): Herpesvirus. Allan R. Liss, New York, 1984, p. 373–385.

    Google Scholar 

  32. Honess, R. W., Purifoy, D. J. M., Young, D., Gopal, R., Cammack, N., O'Hare, P.: Single mutations at many sites within the DNA polymerase locus of herpes simplex viruses can confer hypersensitivity to aphidicolin and resistance to phosphonoacetic acid. Journal of General Virology 1984, 65: 1–17.

    Google Scholar 

  33. Larder, B. A., Kemp, S. D., Darby, G.: Related functional domains in virus DNA polymerase. EMBO Journal 1987, 6: 169–175.

    Google Scholar 

  34. Larder, B. A., Darby, G.: Virus drug-resistance: mechanisms and consequences. Antiviral Research 1984, 4: 1–42.

    Google Scholar 

  35. Chiou, H. C., Weller, S. K., Coen, D. M.: Mutations in the herpes simplex virus major DNA binding protein gene leading to altered sensitivity to DNA polymerase inhibitors. Virology 1985, 145: 213–226.

    Google Scholar 

  36. Allen, L. B., Fingal, C. M.: Failure of type 1 herpesvirus to develop resistance to Ribavirin. Antimicrobial Agents and Chemotherapy 1977, 12: 120–121.

    Google Scholar 

  37. Jawetz, E., Coleman, W. R., Dawson, C. R., Thygeson, P.: The dynamics of IUDR action in herpetic keratitis and the emergence of IUDR-resistance in vivo. Annals of the New York Academy of Science 1970, 173: 282–291.

    Google Scholar 

  38. McGill, J., Scott, G. M.: Viral keratitis. British Medical Bulletin 1985, 41: 351–356.

    Google Scholar 

  39. Hirano, A., Yumura, K., Kurimura, T., Katsumoto, T., Moriyama, H., Manabe, R.: Analysis of herpes simplex virus isolated from patients with recurrent herpes keratitis exhibiting “treatment resistance” to 5-iodo-2′-deoxyuridine. Acta Virologica 1979, 23: 226–230.

    Google Scholar 

  40. Funderburgh, M. L., Funderburgh, J. L., Chandler, J. W.: Thymidine kinase activity of ocular herpes simplex isolates resistant to IDUR therapy. Investigative Ophalmology and Visual Science 1986, 27: 1546–1548.

    Google Scholar 

  41. Anderson, J. R.: The chemotherapy of herpes simplex encephalitis in man. In Field, H. J. (ed.): Anticiral agents: the development and assessment of antiviral chemotherapy. CRC Press, Boca Raton, 1988, p. 1–12.

    Google Scholar 

  42. Parris, D. S., Harrington, J. E.: Herpes simplex virus variants resistant to high concentrations of acyclovir exist in clinical isolates. Antimicrobial Agents and Chemotherapy 1982, 22: 71–77.

    Google Scholar 

  43. Barry, D. W., Lehrman, S. N., Ellis, M. N.: Clinical and laboratory experience with acyclovir-resistant herpes viruses. Journal of Antimicrobial Chemotherapy 1986, 18, Supplement B: 75–84.

    Google Scholar 

  44. McLaren, C., Corey, L., Dekker, C., Barry, D. W.: In vitro sensitivity to acyclovir in genital herpes simplex virus from acyclovir-treated patients. Journal of Infectious Diseases 1983, 148: 868–875.

    Google Scholar 

  45. Collins, P., Oliver, N. M.: Sensitivity monitoring of herpes simplex virus isolates from patients receiving acyclovir. Journal of Antimicrobial Chemotherapy 1986, 18, Supplement B: 103–112.

    Google Scholar 

  46. Martin, J. L., Ellis, M. N., Keller, P. M., Biron, K. K., Lehrman, S. N., Barry, D. W., Furmin, P. A.: Plaque autoradiographic assay for the detection and quantitation of thymidine kinase-deficient and thymidine kinase-altered mutants of herpes simplex in clinical isolates. Antimicrobial Agents and Chemotherapy 1985, 28: 181–187.

    Google Scholar 

  47. Parker, A. C., Craig, J. I. O., Collins, P., Oliver, N., Smith, I.: Acyclovir-resistant herpes simplex virus infection due to altered DNA polymerase. Lancet 1987, ii: 1461.

    Google Scholar 

  48. Anderson, H., Scarfe, J. H., Sutton, R. N. P., Hickmot, E., Brigden, D., Burke, C.: Oral acyclovir prophylaxis against herpes simplex virus in non-Hodgkin lymphoma and acute lymphoblastic leukaemia patients receiving remission induction chemotherapy. A randomised double blind, placebo controlled trial. British Journal of Cancer 1984, 50: 45–49.

    Google Scholar 

  49. Gold, D., Corey, L.: Acyclovir prophylaxis for herpes simplex virus infection. Antimicrobial Agents and Chemotherapy 1987, 31: 361–367.

    Google Scholar 

  50. Strauss, S. E., Takiff, H. E., Seidlin, M., Bachrach, S., Lininger, L., DiGiovanna, J. J., Western, K. A., Smith, H. A., Lehrman, S. N., Creagh-Kirk, T., Alling, D. W.: Suppression of frequently occurring genital herpes. A placebo-controlled double-blind trial with acyclovir. New England Journal of Medicine 1984, 310: 1545–1550.

    Google Scholar 

  51. Harmenberg, J., Sundqvist, V.-A., Gadler, H., Leven, B., Brannstrom, G., Wahren, B.: Comparative methods for detection of thymidine kinase-deficient herpes simplex virus type 1 strains. Antimicrobial Agents and Chemotherapy 1986, 30: 570–573.

    Google Scholar 

  52. Harmenberg, J., Wahren, B., Sundqvist, V.-A., Leven, B.: Multiplicity dependence of sensitivity of herpes simplex virus isolates to antiviral compounds. Journal of Antimicrobial Chemotherapy 1985, 15: 567–573.

    Google Scholar 

  53. Swierkosz, E. M., Scholl, D. R., Brown, J. L., Jollick, J. D., Gleaves, C. A.: Improved DNA hybridization method for detection of acyclovir-resistant herpes simplex virus. Antimicrobial Agents and Chemotherapy 1987, 31: 1465–1469.

    Google Scholar 

  54. Field, H. J.: Development of Antiviral Resistance. In: Field, H. J. (ed.): Antiviral agents, the development and assessment of antiviral chemotherapy. CRC Press, Boca Raton, 1987, p. 127–149.

    Google Scholar 

  55. Burns, W. H., Saral, R., Santos, G. W., Laskin, O. L., Leithan, P. S., McLaren, C., Barry, D. W.: Isolation and characterisation of resistant herpes simplex virus after acyclovir therapy. Lancet 1982, i: 421–423.

    Google Scholar 

  56. Wade, J. C., Newton, B., McLaren, C., Flournoy, N., Keeney, R. E., Meyers, J. D.: Intravenous acyclovir to treat mucocutaneous herpes simplex virus infection after bone marrow transplantation. Annals of Internal Medicine 1982, 96: 265–269.

    Google Scholar 

  57. Crumpacker, C. S., Schnipper, L. E., Marlowe, S. I., Kowalsky, P. N., Hershey, B. J., Levin, M. J.: Resistance to antiviral drugs of herpes simplex virus isolated from a patient treated with acyclovir. New England Journal of Medicine 1982, 306: 343–346.

    Google Scholar 

  58. Field, H. J.: Resistance and latency. British Medical Bulletin 1985, 41: 345–350.

    Google Scholar 

  59. Bean, B., Fletcher, C., Englund, J., Lehrman, S. N., Ellis, M. N.: Progressive mucocutaneous herpes simplex infection due to acyclovir-resistant virus in an immunocompromised patient: correlation of viral susceptibilities and plasma levels with response to therapy. Diagnostic Microbiology and Infectious Disease 1987, 7: 199–204.

    Google Scholar 

  60. Christophers, J., Sutton, R. N. P.: Characterization of acyclovir-resistant and sensitive clinical isolates of herpes simplex virus from an immunocompromised patient. Journal of Antimicrobial Chemotherapy 1987, 20: 389–398.

    Google Scholar 

  61. Sibrack, C. D., Gutman, L. T., Wilfert, C. M., McClaren, C., St. Clair, M. H., Keller, P. M., Barry, D. W.: Pathogenicity of acyclovir-resistant herpes simplex virus type 1 from an immunodeficient child. Journal of Infectious Diseases 1982, 146: 673–682.

    Google Scholar 

  62. Field, H. J., Darby, G.: Pathogenicity in mice of strains of herpes simplex virus which are resistant to acyclovir in vitro and in vivo. Antimicrobial Agents and Chemotherapy 1980, 17: 209–216.

    Google Scholar 

  63. Field, H. J., Owen, L.: The problem of virus drug resistance in antiviral drug development. In: De Clercq, E., Walker, R. T. (ed.): Antiviral drug development: a multidisciplinary approach. Plenum Press, New York, 1988, p. 203–236.

    Google Scholar 

  64. Biron, K. K., Fyfe, J. A., Stanat, S. C., Leslie, L. K., Sorrell, J. B., Lambe, C. U., Coen, D. M.: A human cytomegalvirus mutant resistant to the nucleoside analog 9-([2-hydroxy-1(hydroxymethyl)ethoxy] methyl) guanine (BW B759U) induces reduced levels of BW B759U triphosphate. Proceedings of the National Academy of Sciences of the USA 1986, 83: 8769–8773.

    Google Scholar 

  65. Denis, J., Langois, M., Elkaim, M., Amiel, C., Aymard, M., Huraux, J. M.: HSV1 strain sensitivity in experimental rabbit keratitis: evolution under repeated topical IDU administrations. Current Eye Research 1987, 6: 39–45.

    Google Scholar 

  66. Appleyard, G., Way, H.: Thiosemicarbazone-resistant rabbitpox virus. British Journal of Experimental Pathology 1966, 47: 144–151.

    Google Scholar 

  67. Oxford, J. S., Logan, I. S., Potter, C. W.: In vivo selection of an influenza A2 strain resistant to amantadine. Nature 1970, 226: 82–83.

    Google Scholar 

  68. Webster, R. G., Kawoaka, Y., Bean, W. J.: Vaccination as a strategy to reduce the emergence of amantadine and rimantadine resistant strains of A/chick/Pennsylvania/83 (H5N2) influenza virus. Journal of Antimicrobial Chemotherapy 1986, 18, Supplement B: 157–164.

    Google Scholar 

  69. Beard, C. W., Brugh, M., Webster, R. G.: Emergence of amantadine-resistant H5N2 avian influenza virus during a simulated layer flock treatment program. Avian Diseases 1987, 31: 533–537.

    Google Scholar 

  70. Field, H. J.: Development of clinical resistance to acyclovir in herpes simplex virus-infected mice receiving oral therapy. Antimicrobial Agents and Chemotherapy 1982, 21: 744–752.

    Google Scholar 

  71. Field, H. J., Lay, E.: Characterization of latent infections in mice after inoculation with herpes simplex virus which is clinically resistant to acyclovir. Antiviral Research 1984, 4: 43–52.

    Google Scholar 

  72. Ellis, M. N., Martin, J. L., Lobe, D. C., Johnsrude, J. D., Barry, D. W.: Induction of acyclovir-resistant mutants of herpes simplex virus type 1 in athymic nude mice. Journal of Antimicrobial Chemotherapy 1986, 18, Supplement B: 95–101.

    Google Scholar 

  73. Ellis, M. N., Keller, P. M., Fyfe, J. A., Martin, J. L., Rooney, J. F., Straus, S. E., Nusinoff Lehrman, S., Barry, D. W.: Clinical isolate of herpes simplex type 2 that induces thymidine kinase with altered substrate specificity. Antimicrobial Agents and Chemotherapy 1987, 31: 1117–1125.

    Google Scholar 

  74. De Clercq, E.: New selective antiviral agents active against AIDS viruses. Trends in Pharmacological Science 1987, 8: 339–345.

    Google Scholar 

  75. Shiraki, K., Ogino, T., Yamanishi, K., Takahashi, M.: Isolation of drug resistant mutants of varicella-zoster virus: cross resistance of acyclovir resistant mutant with phosphonoacetic acid and bromodeoxyuridine. Biken Journal 1983, 26: 17–23.

    Google Scholar 

  76. Biron, K. K., Fyfe, J. A., Stanat, S. C., Leslie, L. K., Sorrell, J. B., Lambe, C. U., Coen, D. M.: A human cytomegalovirus mutant resistant to the nucleoside analog 9-([2-hydroxy-1(hydroxymethyl)ethoxy]methyl) guanine (BW B759U) induces reduced levels of BW B759U triphosphate. Proceedings of the National Academy of Sciences of the USA 1986, 83: 8769–8773.

    Google Scholar 

  77. Al-Nakib, W., Yasin, S., Dearden, C. J.: In vitro and in vivo development of drug resistance by rhinoviruses. Antiviral Research 1988, 9: 128.

    Google Scholar 

  78. Pemberton, R. M., Jennings, R., Potter, C. W., Oxford, J. S.: Amantadine resistance in clinical influenza A (H3N2) and (H1N1) virus isolates. Journal of the Antimicrobial Chemotherapy 1986, 18, Supplement B: 135–140.

    Google Scholar 

  79. Larder, B. A., Purifoy, J. M., Powell, K. L., Darby, G.: Site-specific mutagenesis of AIDS virus reverse transcriptase. Nature 1987, 327: 716–717.

    Google Scholar 

  80. Larder, B. A., Darby, C., Richman, D. D.: HIV with reduced sensitivity to zovirudine (AZT) isolated during prolonged therapy. Science 1989, 243: 1731–1734.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Veterinary Medicine, Madingley Rd, CB3 0ES, Cambridge, UK

    H. J. Field

Authors
  1. H. J. Field
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Field, H.J. Persistent herpes simplex virus infection and mechanisms of virus drug resistance. Eur. J. Clin. Microbiol. Infect. Dis. 8, 671–680 (1989). https://doi.org/10.1007/BF01963751

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01963751

Keywords

Search

Navigation